{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:21:02Z","timestamp":1783488062118,"version":"3.55.0"},"reference-count":71,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002661","name":"Fonds De La Recherche Scientifique - FNRS","doi-asserted-by":"publisher","award":["40011958"],"award-info":[{"award-number":["40011958"]}],"id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales d'Endocrinologie"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.ando.2024.03.004","type":"journal-article","created":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T08:21:33Z","timestamp":1712650893000},"page":"300-307","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["How often should we perform magnetic resonance imaging (MRI) for the follow-up of pituitary adenoma?"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2665-9455","authenticated-orcid":false,"given":"Stefan Matei","family":"Constantinescu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Duprez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Bonneville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Maiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ando.2024.03.004_bib0360","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1056\/NEJMra1810772","article-title":"Pituitary-tumor endocrinopathies","volume":"382","author":"Melmed","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2024.03.004_bib0365","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000442327","article-title":"Magnetic resonance imaging of pituitary tumors","volume":"45","author":"Bonneville","year":"2016","journal-title":"Front Horm Res"},{"key":"10.1016\/j.ando.2024.03.004_bib0370","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11102-018-0924-0","article-title":"Physicians\u2019 awareness of gadolinium retention and MRI timing practices in the longitudinal management of pituitary tumors: a \u201cPituitary Society\u201d survey","volume":"22","author":"Nachtigall","year":"2019","journal-title":"Pituitary"},{"key":"10.1016\/j.ando.2024.03.004_bib0375","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1007\/s00330-017-5065-8","article-title":"Gadolinium retention after administration of contrast agents based on linear chelators and the recommendations of the European Medicines Agency","volume":"28","author":"Dekkers","year":"2018","journal-title":"Eur Radiol"},{"key":"10.1016\/j.ando.2024.03.004_bib0380","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1148\/radiol.2016162241","article-title":"No signal intensity increase in the dentate nucleus on unenhanced T1-weighted MR Images after more than 20 serial injections of macrocyclic gadolinium-based contrast agents","volume":"282","author":"Radbruch","year":"2017","journal-title":"Radiology"},{"key":"10.1016\/j.ando.2024.03.004_bib0385","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3174\/ajnr.A5538","article-title":"High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: comparison between gadobutrol and linear gadolinium-based contrast agents","volume":"39","author":"Moser","year":"2018","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1016\/j.ando.2024.03.004_bib0390","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.3174\/ajnr.A7554","article-title":"Do we need gadolinium-based contrast agents for routine MRI surveillance of unoperated pituitary macroadenoma?","volume":"43","author":"Alali","year":"2022","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1016\/j.ando.2024.03.004_bib0395","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/RLI.0000000000000252","article-title":"Macrocyclic and other non-group 1 gadolinium contrast agents deposit low levels of gadolinium in brain and bone tissue: preliminary results from 9 patients with normal renal function","volume":"51","author":"Murata","year":"2016","journal-title":"Invest Radiol"},{"key":"10.1016\/j.ando.2024.03.004_bib0400","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1148\/radiol.2017174037","article-title":"Immediate allergic reactions to gadolinium-based contrast agents: a systematic review and meta-analysis","volume":"286","author":"Behzadi","year":"2018","journal-title":"Radiology"},{"key":"10.1016\/j.ando.2024.03.004_bib0405","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s11102-018-0928-9","article-title":"A plea for the T2W MR sequence for pituitary imaging","volume":"22","author":"Bonneville","year":"2019","journal-title":"Pituitary"},{"key":"10.1016\/j.ando.2024.03.004_bib0410","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s11102-018-00931-x","article-title":"Long term MRI surveillance of pituitary macroadenomas: gadolinium is not obligatory","volume":"22","author":"Bonneville","year":"2019","journal-title":"Pituitary"},{"key":"10.1016\/j.ando.2024.03.004_bib0415","doi-asserted-by":"crossref","first-page":"101290","DOI":"10.1016\/j.beem.2019.101290","article-title":"The epidemiology, diagnosis and treatment of prolactinomas: the old and the new","volume":"33","author":"Chanson","year":"2019","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2024.03.004_bib0420","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/s41574-023-00886-5","article-title":"Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement","volume":"19","author":"Petersenn","year":"2023","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.ando.2024.03.004_bib0425","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1210\/jcem-68-2-412","article-title":"The natural history of untreated hyperprolactinemia: a prospective analysis","volume":"68","author":"Schlechte","year":"1989","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2024.03.004_bib0430","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11102-019-01001-6","article-title":"Magnetic resonance imaging in the management of prolactinomas; a review of the evidence","volume":"23","author":"Varlamov","year":"2020","journal-title":"Pituitary"},{"key":"10.1016\/j.ando.2024.03.004_bib0435","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2265.2010.03808.x","article-title":"Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women","volume":"73","author":"Lebbe","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ando.2024.03.004_bib0440","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline","volume":"96","author":"Melmed","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2024.03.004_bib0445","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s12020-017-1444-9","article-title":"Optimal timing of dopamine agonist withdrawal in patients with hyperprolactinemia: a systematic review and meta-analysis","volume":"59","author":"Xia","year":"2018","journal-title":"Endocrine"},{"key":"10.1016\/j.ando.2024.03.004_bib0450","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/cen.14714","article-title":"Withdrawal of dopamine agonist treatment in patients with hyperprolactinaemia: a systematic review and meta-analysis","volume":"97","author":"Andersen","year":"2022","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ando.2024.03.004_bib0455","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s11102-013-0473-5","article-title":"Is a stable or decreasing prolactin level in a patient with prolactinoma a surrogate marker for lack of tumor growth?","volume":"17","author":"Alkabbani","year":"2014","journal-title":"Pituitary"},{"key":"10.1016\/j.ando.2024.03.004_bib0460","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1530\/EJE-21-0561","article-title":"Shrinkage by the third month predicts long-term response of macroprolactinoma after cabergoline","volume":"185","author":"Biagetti","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2024.03.004_bib0465","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1530\/EJE-16-0897","article-title":"MRI follow-up is unnecessary in patients with macroprolactinomas and long-term normal prolactin levels on dopamine agonist treatment","volume":"176","author":"Eroukhmanoff","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2024.03.004_bib0470","doi-asserted-by":"crossref","first-page":"e686","DOI":"10.1016\/j.wneu.2019.05.249","article-title":"Radiographic and hormonal regression in prolactinomas: an analysis of treatment failure","volume":"129","author":"Akinduro","year":"2019","journal-title":"World Neurosurg"},{"key":"10.1016\/j.ando.2024.03.004_bib0475","series-title":"Prolactinoma and dopamine agonists. MRI of the pituitary gland","first-page":"45","author":"Bonneville","year":"2016"},{"key":"10.1016\/j.ando.2024.03.004_bib0480","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s12020-021-02701-5","article-title":"Outcome of pituitary hormone deficits after surgical treatment of nonfunctioning pituitary macroadenomas","volume":"73","author":"Alexopoulou","year":"2021","journal-title":"Endocrine"},{"key":"10.1016\/j.ando.2024.03.004_bib0485","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00401-013-1084-y","article-title":"A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up","volume":"126","author":"Trouillas","year":"2013","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.ando.2024.03.004_bib0490","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3171\/2014.12.JNS141083","article-title":"Invasion of the cavernous sinus space in pituitary adenomas: endoscopic verification and its correlation with an MRI-based classification","volume":"122","author":"Micko","year":"2015","journal-title":"J Neurosurg"},{"key":"10.1016\/j.ando.2024.03.004_bib0495","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1159\/000499382","article-title":"Clinical, pathological, and molecular factors of aggressiveness in lactotroph tumours","volume":"109","author":"Trouillas","year":"2019","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.ando.2024.03.004_bib0500","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-21-0462","article-title":"ESE Clinical Practice Guideline on functioning and nonfunctioning pituitary adenomas in pregnancy","volume":"185","author":"Luger","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2024.03.004_bib0505","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1530\/EJE-21-0145","article-title":"Apoplexy of microprolactinomas during pregnancy: report of five cases and review of the literature","volume":"185","author":"Kuhn","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2024.03.004_bib0510","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/cen.12370","article-title":"Outcome of prolactinoma after pregnancy and lactation: a study on 73 patients","volume":"80","author":"Domingue","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ando.2024.03.004_bib0515","doi-asserted-by":"crossref","first-page":"104081","DOI":"10.1016\/j.lpm.2021.104081","article-title":"Pituitary incidentaloma","volume":"50","author":"Constantinescu","year":"2021","journal-title":"Presse Med"},{"key":"10.1016\/j.ando.2024.03.004_bib0520","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/j.1365-2265.2007.02990.x","article-title":"What is the natural history of nonoperated nonfunctioning pituitary adenomas?","volume":"67","author":"Karavitaki","year":"2007","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ando.2024.03.004_bib0525","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.beem.2009.05.001","article-title":"Pituitary tumours: pituitary incidentalomas","volume":"23","author":"Molitch","year":"2009","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2024.03.004_bib0530","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/cen.14877","article-title":"Natural history of nonfunctioning pituitary macroadenomas followed without intervention: a retrospective cohort study","volume":"98","author":"Ayalon-Dangur","year":"2023","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"12","key":"10.1016\/j.ando.2024.03.004_bib0535","doi-asserted-by":"crossref","DOI":"10.1530\/EC-23-0224","article-title":"Natural history and surgical outcome of incidentally discovered clinically nonfunctioning pituitary macroadenomas","volume":"12","author":"Constantinescu","year":"2023","journal-title":"Endocr Connect"},{"key":"10.1016\/j.ando.2024.03.004_bib0540","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1210\/jc.2010-1048","article-title":"Pituitary incidentaloma: an endocrine society clinical practice guideline","volume":"96","author":"Freda","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2024.03.004_bib0545","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ando.2015.04.002","article-title":"Management of clinically non-functioning pituitary adenoma","volume":"76","author":"Chanson","year":"2015","journal-title":"Ann Endocrinol (Paris)"},{"key":"10.1016\/j.ando.2024.03.004_bib0550","doi-asserted-by":"crossref","first-page":"e1231","DOI":"10.1210\/clinem\/dgab748","article-title":"Nonfunctioning pituitary microadenomas: should imaging interval be extended?. A large single-center cohort study","volume":"107","author":"Han","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2024.03.004_bib0555","doi-asserted-by":"crossref","first-page":"298","DOI":"10.7326\/M22-1728","article-title":"Long-term changes in the size of pituitary microadenomas","volume":"176","author":"Hordejuk","year":"2023","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ando.2024.03.004_bib0560","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/ejendo\/lvad070","article-title":"Natural history of non-functioning pituitary microadenomas: results from the UK non-functioning pituitary adenoma consortium","volume":"189","author":"Hamblin","year":"2023","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2024.03.004_bib0565","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s11102-022-01289-x","article-title":"Post-operative surveillance for somatotroph, lactotroph and non-functional pituitary adenomas after curative resection: a systematic review","volume":"26","author":"Caulley","year":"2023","journal-title":"Pituitary"},{"key":"10.1016\/j.ando.2024.03.004_bib0570","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1530\/EJE-10-0255","article-title":"Factors predicting relapse of nonfunctioning pituitary macroadenomas after neurosurgery: a study of 142 patients","volume":"163","author":"Brochier","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2024.03.004_bib0575","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1210\/jc.2005-2552","article-title":"Observation alone after transsphenoidal surgery for nonfunctioning pituitary macroadenoma","volume":"91","author":"Dekkers","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2024.03.004_bib0580","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1530\/EJE-11-0566","article-title":"Can we ever stop imaging in surgically treated and radiotherapy-naive patients with non-functioning pituitary adenoma?","volume":"165","author":"Reddy","year":"2011","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.ando.2024.03.004_bib0585","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3390\/cancers12020514","article-title":"How to classify the Pituitary Neuroendocrine Tumors (PitNET)s in 2020","volume":"12","author":"Trouillas","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ando.2024.03.004_bib0590","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.1210\/jc.2017-00773","article-title":"Risk of recurrence in pituitary neuroendocrine tumors: a prospective study using a five-tiered classification","volume":"102","author":"Raverot","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2024.03.004_bib0595","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1530\/EJE-17-0965","article-title":"Both invasiveness and proliferation criteria predict recurrence of non-functioning pituitary macroadenomas after surgery: a retrospective analysis of a monocentric cohort of 120 patients","volume":"178","author":"Lelotte","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2024.03.004_bib0600","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1530\/EJE-18-0749","article-title":"Validation of a clinicopathological score for the prediction of post-surgical evolution of pituitary adenoma: retrospective analysis on 566 patients from a tertiary care centre","volume":"180","author":"Asioli","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2024.03.004_bib0605","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1530\/EJE-22-0812","article-title":"Real-life clinical impact of a five-tiered classification of pituitary tumors","volume":"187","author":"Sahakian","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2024.03.004_bib0610","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1007\/s11102-023-01319-2","article-title":"Usefulness of a clinicopathological classification in predicting treatment-related outcomes and multimodal therapeutic approaches in pituitary adenoma patients: retrospective analysis on a Portuguese cohort of 129 patients from a tertiary pituitary center","volume":"26","author":"Peixe","year":"2023","journal-title":"Pituitary"},{"key":"10.1016\/j.ando.2024.03.004_bib0615","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/ejendo\/lvad079","article-title":"Predictors of pituitary tumour behaviour: an analysis from long-term follow-up in 2 tertiary centres","volume":"189","author":"Lenders","year":"2023","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2024.03.004_bib0620","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.neurad.2022.08.003","article-title":"Is systematic gadolinium injection relevant during MRI follow-up for non-functioning pituitary macroadenomas?","volume":"50","author":"Villemaire","year":"2023","journal-title":"J Neuroradiol"},{"key":"10.1016\/j.ando.2024.03.004_bib0625","doi-asserted-by":"crossref","first-page":"e13123","DOI":"10.1111\/jne.13123","article-title":"Pituitary MRI in Cushing's disease - an update","volume":"34","author":"Bonneville","year":"2022","journal-title":"J Neuroendocrinol"},{"key":"10.1016\/j.ando.2024.03.004_bib0630","doi-asserted-by":"crossref","first-page":"4320","DOI":"10.1210\/jc.2003-032141","article-title":"Pituitary magnetic resonance imaging is not required in the postoperative follow-up of acromegalic patients with long-term biochemical cure after transsphenoidal surgery","volume":"89","author":"Zirkzee","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2024.03.004_bib0635","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1210\/jc.2007-2013","article-title":"Late recurrences of Cushing's disease after initial successful transsphenoidal surgery","volume":"93","author":"Patil","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2024.03.004_bib0640","doi-asserted-by":"crossref","first-page":"M107","DOI":"10.1530\/EJE-15-0616","article-title":"A role for 11C-methionine PET imaging in ACTH-dependent Cushing's syndrome","volume":"173","author":"Koulouri","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2024.03.004_bib0645","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1530\/EJE-16-0639","article-title":"Successful treatment of residual pituitary adenoma in persistent acromegaly following localisation by 11C-methionine PET co-registered with MRI","volume":"175","author":"Koulouri","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2024.03.004_bib0650","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s11102-022-01229-9","article-title":"(11)C-methionine PET aids localization of microprolactinomas in patients with intolerance or resistance to dopamine agonist therapy","volume":"25","author":"Bashari","year":"2022","journal-title":"Pituitary"},{"key":"10.1016\/j.ando.2024.03.004_bib0655","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13550-022-00899-7","article-title":"Localization of TSH-secreting pituitary adenoma using 11C-methionine image subtraction","volume":"12","author":"Gillett","year":"2022","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.ando.2024.03.004_bib0660","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1530\/EJE-19-0681","article-title":"Is MRI follow-up relevant in patients with GH-secreting pituitary adenomas primarily treated and responsive to long-acting somatostatin analogues (SMSa)?","volume":"182","author":"Grandgeorge","year":"2020","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2024.03.004_bib0665","doi-asserted-by":"crossref","first-page":"P1","DOI":"10.1530\/EJE-20-1088","article-title":"Corticotroph tumor progression after bilateral adrenalectomy (Nelson's syndrome): systematic review and expert consensus recommendations","volume":"184","author":"Reincke","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2024.03.004_bib0670","doi-asserted-by":"crossref","first-page":"e2882","DOI":"10.1210\/clinem\/dgac178","article-title":"Randomized trial of osilodrostat for the treatment of Cushing Disease","volume":"107","author":"Gadelha","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2024.03.004_bib0675","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1530\/EJE-07-0514","article-title":"Ketoconazole revisited: a preoperative or postoperative treatment in Cushing's disease","volume":"158","author":"Castinetti","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2024.03.004_bib0680","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s11102-018-0868-4","article-title":"Management of nonfunctioning pituitary tumors: radiotherapy","volume":"21","author":"Minniti","year":"2018","journal-title":"Pituitary"},{"key":"10.1016\/j.ando.2024.03.004_bib0685","doi-asserted-by":"crossref","first-page":"101269","DOI":"10.1016\/j.beem.2019.04.003","article-title":"The risk\/benefit ratio of radiotherapy in pituitary tumors","volume":"33","author":"Minniti","year":"2019","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2024.03.004_bib0690","doi-asserted-by":"crossref","first-page":"919","DOI":"10.2214\/ajr.177.4.1770919","article-title":"MR imaging of pituitary adenomas after gamma knife stereotactic radiosurgery","volume":"177","author":"Tung","year":"2001","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.ando.2024.03.004_bib0695","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S2213-8587(22)00160-7","article-title":"Risk of second brain tumour after radiotherapy for pituitary adenoma or craniopharyngioma: a retrospective, multicentre, cohort study of 3679 patients with long-term imaging surveillance","volume":"10","author":"Hamblin","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ando.2024.03.004_bib0700","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1210\/er.2015-1042","article-title":"Pituitary apoplexy","volume":"36","author":"Briet","year":"2015","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ando.2024.03.004_bib0705","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1080\/02688690601046678","article-title":"Pituitary apoplexy: retrospective review of 30 patients--is surgical intervention always necessary?","volume":"20","author":"Gruber","year":"2006","journal-title":"Br J Neurosurg"},{"key":"10.1016\/j.ando.2024.03.004_bib0710","first-page":"21","article-title":"Conservative management of complicated Rathke's cleft cyst mimicking pituitary apoplexy","volume":"2022","author":"Constantinescu","year":"2022","journal-title":"Endocrinol Diabetes Metab Case Rep"}],"container-title":["Annales d'Endocrinologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426624000490?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426624000490?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T10:42:06Z","timestamp":1728470526000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003426624000490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":71,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S0003426624000490"],"URL":"https:\/\/doi.org\/10.1016\/j.ando.2024.03.004","relation":{},"ISSN":["0003-4266"],"issn-type":[{"value":"0003-4266","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How often should we perform magnetic resonance imaging (MRI) for the follow-up of pituitary adenoma?","name":"articletitle","label":"Article Title"},{"value":"Annales d'Endocrinologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2024.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}